Gotham Asset Management LLC grew its stake in shares of Celgene (NASDAQ:CELG) by 2.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 200,934 shares of the biopharmaceutical company’s stock after acquiring an additional 5,581 shares during the period. Gotham Asset Management LLC’s holdings in Celgene were worth $20,969,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the company. Jump Trading LLC lifted its holdings in shares of Celgene by 160,950.0% in the fourth quarter. Jump Trading LLC now owns 3,217 shares of the biopharmaceutical company’s stock valued at $336,000 after purchasing an additional 3,219 shares in the last quarter. Palo Alto Investors LLC lifted its holdings in shares of Celgene by 4.3% in the fourth quarter. Palo Alto Investors LLC now owns 307,940 shares of the biopharmaceutical company’s stock valued at $32,137,000 after purchasing an additional 12,700 shares in the last quarter. Redmile Group LLC purchased a new stake in shares of Celgene in the fourth quarter valued at $68,147,000. BB&T Securities LLC lifted its holdings in shares of Celgene by 22.5% in the fourth quarter. BB&T Securities LLC now owns 52,364 shares of the biopharmaceutical company’s stock valued at $5,464,000 after purchasing an additional 9,606 shares in the last quarter. Finally, HBK Sorce Advisory LLC lifted its holdings in shares of Celgene by 12.2% in the fourth quarter. HBK Sorce Advisory LLC now owns 14,681 shares of the biopharmaceutical company’s stock valued at $1,532,000 after purchasing an additional 1,598 shares in the last quarter. Institutional investors own 78.53% of the company’s stock.
Shares of NASDAQ:CELG opened at $91.01 on Thursday. The company has a quick ratio of 4.80, a current ratio of 4.99 and a debt-to-equity ratio of 2.29. The firm has a market cap of $68,101.98, a P/E ratio of 13.31, a PEG ratio of 0.61 and a beta of 1.49. Celgene has a 1 year low of $84.25 and a 1 year high of $147.17.
Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The firm had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The business’s quarterly revenue was up 16.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.61 earnings per share. analysts anticipate that Celgene will post 7.66 earnings per share for the current year.
Celgene declared that its board has approved a stock buyback program on Wednesday, February 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.
A number of analysts have recently issued reports on CELG shares. Sanford C. Bernstein lowered Celgene from an “outperform” rating to a “market perform” rating and set a $121.00 target price for the company. in a report on Wednesday, December 27th. SunTrust Banks restated a “buy” rating and issued a $139.00 target price (up previously from $127.00) on shares of Celgene in a report on Friday, January 26th. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 target price for the company in a report on Thursday, January 25th. Zacks Investment Research lowered Celgene from a “hold” rating to a “sell” rating in a report on Tuesday, December 26th. Finally, Mizuho set a $128.00 target price on Celgene and gave the company a “buy” rating in a report on Friday, January 5th. Four investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $126.95.
In other Celgene news, insider Mark J. Alles bought 3,260 shares of the stock in a transaction on Thursday, February 8th. The shares were purchased at an average cost of $91.90 per share, with a total value of $299,594.00. Following the completion of the transaction, the insider now directly owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $95.99, for a total transaction of $887,907.50. Following the transaction, the director now directly owns 94,801 shares in the company, valued at $9,099,947.99. The disclosure for this sale can be found here. Insiders have sold 41,120 shares of company stock worth $3,879,509 over the last three months. Company insiders own 0.95% of the company’s stock.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.